Latest news with #FSE
Business Wire
3 hours ago
- Business
- Business Wire
Spanish Mountain Gold Announces Completion of Shares For Debt
VANCOUVER, British Columbia--(BUSINESS WIRE)--Spanish Mountain Gold Ltd. (the "Company" or "Spanish Mountain Gold") (TSX-V: SPA) (FSE: S3Y) (OTCQB: SPAUF) is pleased to announce that, further to the Company's news release on July 4, 2025, the Company has completed a shares for debt transaction with Whittle Consulting Ltd., an arm's length creditor of the Company ('Whittle') to settle an aggregate of $379,720 in outstanding debt (the 'Debt'). In settlement of the Debt, the Company has (i) paid Whittle $14,320, in cash, and (ii) issued 2,110,919 common shares in the capital of the Company (the 'Shares') as directed by Whittle at a price of $0.1731 per Share (the 'Debt Settlement'). The Debt Settlement extinguishes the Debt owed to Whittle for past services to the Company. Closing of the Debt Settlement was subject to a number of customary closing conditions, including, but not limited to, approval from the TSX Venture Exchange. The Shares are subject to a statutory four month plus a day hold period in accordance with applicable securities legislation. About Spanish Mountain Gold Ltd. Spanish Mountain Gold Ltd. is focused on advancing its 100%-owned Spanish Mountain Gold Project (Project) towards construction of the next gold mine in the Cariboo Gold Corridor, British Columbia. The Company will publish, within 45 days of the July 3, 2025 Preliminary Economic Assessment (PEA) news release, a new NI 43-101 Technical Report setting out the new executable vision to advance the Project. This new NI 43-101 Technical Report, with a de-risked and optimized PEA with an updated Mineral Resource Estimate (MRE), will supersede the prior technical report of the Company. Upon receipt of the new PEA and updated MRE, the Company will decide the next steps to advance the Project to position the Company to make a construction decision in or before 2027. We are striving to be a leader in community and Indigenous relations by leveraging technology and innovation to build the 'greenest' gold mine in Canada. The Relentless Pursuit for Better Gold means seeking new ways to achieve optimal financial outcomes that are safer, minimize environmental impact and create meaningful sustainability for communities. Details of the Company are available on and on the Company's website: On Behalf of the Board, 'Peter Mah' President, Chief Executive Officer and Director Spanish Mountain Gold Ltd. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. FORWARD-LOOKING INFORMATION: Certain of the statements and information in this press release constitute "forward-looking information". Any statements or information that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects", "anticipates", "believes", "plans", "estimates", "intends", "targets", "goals", "forecasts", "objectives", "potential" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be considered forward-looking information. The Company's forward-looking information is based on the assumptions, beliefs, expectations and opinions of management as of the date of this press release and include but are not limited to information with respect to, the potential to extend mineralization within the near-surface environment; the potential to expand resources and to find higher-grade mineralization at depth; the timing, size and budget of a winter drill program, and the results thereof; and the delivery of a maiden resource for the Phoenix Target, and the timing and results thereof. Other than as required by applicable securities laws, the Company does not assume any obligation to update forward-looking information if circumstances or management's assumptions, beliefs, expectations or opinions should change, or changes in any other events affecting such statements or information. For the reasons set forth above, investors should not place undue reliance on forward-looking information.
Cision Canada
4 hours ago
- Business
- Cision Canada
BTQ Technologies Corp. Announces Closing of C$40 Million Prospectus Offering Led by a New Fundamental Long-Term Investor English
VANCOUVER, BC and TAIPEI, Taiwan, July 11, 2025 /CNW/ - BTQ Technologies Corp. (" BTQ" or the " Company") (CBOE CA: BTQ) (FSE: NG3) (OTCQX: BTQQF), a global quantum technology company focused on securing mission-critical networks is pleased to announce the closing of its public offering (the " Offering") pursuant to a prospectus supplement dated July 9, 2025 (" Prospectus Supplement") to the Company's short form base shelf prospectus dated April 29, 2025 (" Base Shelf"). The Offering was led by a new fundamental, long-term institutional investor, alongside participation from existing shareholders and new high-quality institutional investors. The Offering was completed on a best-efforts agency basis pursuant to an agency agreement (the " Agency Agreement") between the Company and A.G.P. Canada Investments ULC (the " Agent") dated July 9, 2025. Pursuant to the Offering, the Company has issued 5,555,555 common shares of the Company (" Common Shares") at a price of C$7.20 per Common Share, for aggregate gross proceeds of approximately C$40,000,000. The Agent acted as the sole bookrunner and agent for the Offering and A.G.P./Alliance Global Partners acted as sole U.S. placement agent for the Offering. The Company intends to use the net proceeds from the Offering for general corporate purposes, working capital and to accelerate the development of both hardware and software products and potential acquisitions. Pursuant to the terms of the Agency Agreement, the Company paid the Agent a cash fee equal to 7% of the gross proceeds from the Offering and issued to the Agent non-transferable broker warrants (the " Broker Warrants") equal to 2.5% of the total number of Common Shares sold pursuant to the Offering. Each Broker Warrant will be exercisable for one Common Share at a price of C$12.60 per Broker Warrant and is exercisable for a period of 60 months following the completion of the Offering. The Prospectus Supplement, Base Shelf and continuous disclosure documents are available on SEDAR+ at and contain important information about the Offering and the Company. The securities to be offered pursuant to the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act") or under any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, a "U.S. person" (as defined in Regulation S under the U.S. Securities Act) absent registration or any applicable exemption from the registration requirements under the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About BTQ BTQ Technologies Corp. (Cboe CA: BTQ | FSE: NG3 | OTCQX: BTQQF) is a vertically integrated quantum company accelerating the transition from classical networks to the quantum internet. Backed by a broad patent portfolio, BTQ pioneered the industry's first commercially significant quantum advantage and now delivers a full-stack, neutral-atom quantum computing platform with end-to-end hardware, middleware, and post-quantum security solutions for finance, telecommunications, logistics, life sciences, and defense. Forward-Looking Information: Certain statements or information contained in this news release may constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, " forward-looking information"). Such forward-looking information includes but is not limited to statements or information with respect to the business plans of the Company, including with respect to its research partnerships, its development of hardware and software products, its potential acquisitions, and its use of proceeds from the Offering. Forward-looking information often can be identified by the use of words such as "anticipate", "intend", "expect", "plan" or "may" and the variations of these words are intended to identify forward-looking information. The Company has made numerous assumptions including, without limitation, assumptions about: general business and economic conditions; that net proceeds from the Offering will accelerate the development of both hardware and software products and potential acquisitions; the nature of investors who participated in the Offering; and the development of post-quantum algorithms and quantum vulnerabilities, and the quantum computing industry generally. The foregoing list of assumptions is not exhaustive. Although management of the Company believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that forward-looking information herein will prove to be accurate. Forward-looking information is based on assumptions and involve known and unknown risks which may cause actual results to be materially different from any future results, expressed or implied, by such forward-looking information. These factors include risks relating to: the availability of financing for the Company; business and economic conditions in the post-quantum and encryption computing industries generally; the speculative nature of the Company's research and development programs; the supply and demand for labour and technological post-quantum and encryption technology; unanticipated events related to regulatory and licensing matters and environmental matters; changes in general economic conditions or conditions in the financial markets; changes in laws (including regulations respecting blockchains); risks related to the impact on general economic conditions, the ability to obtain financing as required, and causing potential delays to research and development activities; and other risk factors as detailed from time to time. More information about the risks and uncertainties affecting the Company's business can be found in the " Risk Factors" section of its Annual Information Form for the year ended December 31, 2024 and in the Company's most recently filed management's discussion and analysis, copies of which are available under the Company's profile on SEDAR+ at The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. SOURCE BTQ Technologies Corp.
Toronto Star
5 hours ago
- Business
- Toronto Star
Hydreight to Participate in the Canaccord Genuity 45th Annual Growth Conference in Boston
VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) ('Hydreight' or the 'Company'), a telehealth and mobile medical company operating across the U.S. focused on expanding access to care, is pleased to announce it has been invited to participate in the Canaccord Genuity 45th Annual Growth Conference, taking place in Boston, Massachusetts on August 12 and 13, 2025. The CG Growth Conference is a well-recognized investment event connecting innovative public and private companies with institutional investors from around the world. Hydreight's participation underscores its position as a key player in the evolving healthcare landscape, providing a vertically integrated, 50-state compliant platform for mobile, on-demand medical services across America.
Hamilton Spectator
5 hours ago
- Business
- Hamilton Spectator
Hydreight to Participate in the Canaccord Genuity 45th Annual Growth Conference in Boston
VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) ('Hydreight' or the 'Company'), a telehealth and mobile medical company operating across the U.S. focused on expanding access to care, is pleased to announce it has been invited to participate in the Canaccord Genuity 45th Annual Growth Conference, taking place in Boston, Massachusetts on August 12 and 13, 2025. The CG Growth Conference is a well-recognized investment event connecting innovative public and private companies with institutional investors from around the world. Hydreight's participation underscores its position as a key player in the evolving healthcare landscape, providing a vertically integrated, 50-state compliant platform for mobile, on-demand medical services across America. Hydreight will be represented by Shane Madden, Chief Executive Officer, and Shafin Diamond Tejani, Board Chair, who will meet one-on-one with investors and participate in discussions around the Company's rapid revenue growth, national expansion strategy, and pipeline of new wellness, pharmacy, and telehealth offerings. 'We're honored to be invited to one of the industry's most respected investor conferences,' said Shane Madden, CEO of Hydreight. 'This is a fantastic opportunity to share our vision and momentum with leading institutions as we continue to scale our infrastructure and expand access to compliant, on-demand healthcare across the country.' Investor Webinar – Thursday, July 24 Join Hydreight for a live investor webinar as management will deep dive into the Perfect Scripts Acquisition: Thursday, July 24, 2025 11:15 AM – 11:45 AM PT Includes live investor Q&A related to the deal Click here to register For context ahead of the call, investors can review Hydreight's recent Q1 financial results here: Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth On behalf of the Board of Directors Shane Madden Director and Chief Executive Officer Hydreight Technologies Inc. Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company Contact Email: ir@ ; Telephone: 1 (702) 970-8112 About Hydreight Technologies Inc. Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network. About VSDHOne - Direct to Consumer Platform Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (TRT), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward Looking Information This news release contains forward looking information or statements within the meaning of applicable securities laws, which may include, without limitation, statements relating to the terms and completion of the Transaction, including the entry into a Definitive Agreement, the receipt of corporate, regulatory and stock exchange approval in respect of the Transaction, the business prospects of the Company, the perceived benefits of the Transaction and a strategic partnership between the Company and Perfect Scripts, and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward looking information or statements. Although the Company believes the expectations expressed in such forward-looking information or statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking information or statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, the ability to achieve its goals, expected costs and timelines to achieve the Company's goals, that general business and economic conditions will not change in a material adverse manner, and that financing will be available if and when needed and on reasonable terms. Such forward looking information or statements reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties included in in documents filed under the Company's profile on SEDAR+ at . While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive, and regulatory uncertainties and risks. Factors that could cause actual results to differ materially from those in forward looking information or statements include, but are not limited to, the ability of the Company to complete the Transaction on the terms described herein, including obtaining the requisite regulatory and stock exchange approvals, continued availability of capital and financing and general economic, market or business conditions, failure to compete effectively with competitors, failure to maintain or obtain all necessary permits, approvals and authorizations, failure to comply with applicable laws, including environmental laws, risks relating to unanticipated operational difficulties. The Company does not undertake to update forward looking statements or forward-looking information, except as required by law. All data about the PerfectScript and its subsidiaries are provided by its management team and Hydreight is performing its full Due Diligent before completing this transaction.
Cision Canada
6 hours ago
- Business
- Cision Canada
Else Nutrition Applauds Pivotal U.S. Legislative Support for Plant-Based, Non-Soy, Non-Dairy Infant Formula Innovation
House Appropriations Committee Champions Greater Nutritional Choice and Market Access for U.S. Families FDA Directed to Streamline Approval Pathways for Plant-Based Infant Formulas, Positioning Else Nutrition to Capitalize on Legislative Momentum and Rising Consumer Demand VANCOUVER, BC, July 22, 2025 /CNW/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) ("Else" or the"Company"), a global leader in wholefood, plant-pased childhood nutrition for babies, toddlers, children and adults, today applauds the U.S. House of Representatives Committee on Appropriations for the full-committee passage of the FY2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill. This landmark legislation includes vital language recognizing the importance of expanding access to alternative infant formulas—specifically plant-based, non-soy, and non-dairy formulations—for a growing number of American families. The accompanying report directs the U.S. Food and Drug Administration (FDA) to streamline approval pathways for small domestic manufacturers and calls for formal regulatory guidance around non-dairy, non-soy plant-based formulas. These are critical for infants with allergies, intolerances, or sensitivities to traditional ingredients—as well as for families seeking nutritional alternatives aligned with health, lifestyle, or ethical values. "This marks a turning point for American families and for Else Nutrition," said Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. "For too long, parents have had to choose between limited formula options that may not meet their child's needs. This legislative milestone signals that change is coming—toward a more inclusive and diversified infant formula landscape. We commend Congress for recognizing this urgent need and taking action that we believe will benefit families for generations to come." Although these types of advanced formulas have gained traction in global markets, regulatory delays have historically constrained innovation in the U.S. market. The recently advanced legislative language is a strong signal to the FDA to establish clear, actionable guidance that can accelerate the availability of safe, effective, and scientifically backed alternatives. The report also highlights the Operation Stork Speed initiative, part of the Administration's broader effort to fast-track innovation in the infant formula space. By elevating plant-based, non-dairy, non-soy formulations as a key component of this initiative, the legislation reinforces the national commitment to nutritional accessibility and product diversity. While additional legislative steps remain—including passage by the full House—the inclusion of this language in the committee's final report is a powerful indication of Congressional momentum. Though report language is non-binding, it frequently shapes agency priorities, resource allocation, and the pace at which new regulatory frameworks are developed. For Else Nutrition, the implications are clear: the path to broader U.S. market access is becoming more defined. "This is the clearest signal yet that U.S. policymakers are aligned with what we at Else have long championed—that every child deserves access to safe, effective, and nutritionally complete formula options," Yitzhak added. "We look forward to supporting this important public health mission by working with the FDA and other federal partners to help bring innovative solutions to more families, more quickly." DISCLAIMERS This grassroots lobbying effort is a statement of issue advocacy and does not require disclosure under the Lobbying Disclosure Act. This is not an electioneering statement, and this message has not been coordinated with any political parties or candidates. This message is paid for by Else Nutrition and is intended for only a "restricted class" of stockholders and administrators of the company. Whereas this is an instance of grassroots lobbying, Else Nutrition's engaged lobbying principals file disclosures required under the Lobbying Disclosure Act for direct lobbying services on behalf of the company. About Else Nutrition Holdings Inc. Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and Plant-Based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, Plant-Based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth. Awards and Recognition: "2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category "Best Dairy Alternative" Award 2021 at World Plant-Based Expo Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle category During September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on Amazon TSX Neither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release. Caution Regarding Forward-Looking Statements This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. SOURCE Else Nutrition Holdings Inc.
